Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie
Schlaeppi M, Templeton A. Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie. Onkologische Pharmazie 2015; 1:46-50.
01.01.2015Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie
01.01.2015Onkologische Pharmazie 2015; 1:46-50
Schlaeppi Marc, Templeton Arnoud
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin Radiol 2014
30.12.2014Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
30.12.2014Clin Radiol 2014
Pezaro C, Sohaib A, de Bono J S, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin Aurelius, Tunariu N
The Swiss Working Group Brain Tumor
Hundsberger T. The Swiss Working Group Brain Tumor. Eur Assoc neurooncol Mag 2014; 4:134-135.
30.12.2014The Swiss Working Group Brain Tumor
30.12.2014Eur Assoc neurooncol Mag 2014; 4:134-135
Hundsberger Thomas
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014
23.12.2014Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
23.12.2014Ann Oncol 2014
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton Arnoud, Mateo J, de Bono J S
RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?
Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, Schwitter M. RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?. Oncology 2014; 88:257-260.
17.12.2014RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?
17.12.2014Oncology 2014; 88:257-260
Cathomas Richard, Rothermundt Christian, Bode Beata, Fuchs Bruno, von Moos Roger, Schwitter Michael
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†. Ann Oncol 2014
15.12.2014Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
15.12.2014Ann Oncol 2014
van Soest R J, Tannock I F, Eisenberger M A, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F E, Templeton Arnoud, De Wit R
Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
Kroeger N, Smoragiewicz M, Lee J, Rini B, Vaishampayan U, Wood L, Beuselinck B, Donskov F, Choueiri T, Bernstein E, Knox J, Templeton A, Pantuck A, Wells J, Lawrence N, Broom R, Kim J, Srinivas S, Yim J, Bjarnason G, Heng D. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol 2014
15.12.2014Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
15.12.2014Eur Urol 2014
Kroeger Nils, Smoragiewicz Martin, Lee Jae, Rini Brian I, Vaishampayan Ulka N, Wood Lori A, Beuselinck Benoit, Donskov Frede, Choueiri Toni K, Bernstein Ezra, Knox Jennifer, Templeton Arnoud, Pantuck Allan J, Wells J Connor, Lawrence Nicola, Broom Reuben, Kim Jenny J, Srinivas Sandy, Yim Jessica, Bjarnason Georg A, Heng Daniel Y
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
Klauschen F, Denkert C, Dietel M, Lederer B, Mehta K, Erbstößer E, Rüdiger T, Huober J, Blohmer J, Gerber B, Loibl S, Schmitt W, Wienert S, von Minckwitz G. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res 2014; 21:3651-7.
11.12.2014Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
11.12.2014Clin Cancer Res 2014; 21:3651-7
Klauschen Frederick, Denkert Carsten, Dietel Manfred, Lederer Bianca, Mehta Keyur, Erbstößer Erhard, Rüdiger Thomas, Huober Jens, Blohmer Jens-Uwe, Gerber Bernd, Loibl Sibylle, Schmitt Wolfgang D, Wienert Stephan, von Minckwitz Gunter
Objective consensus from decision trees
Putora P, Panje C, Papachristofilou A, Pra A, Hundsberger T, Plasswilm L. Objective consensus from decision trees. Radiat Oncol 2014; 9:270.
05.12.2014Objective consensus from decision trees
05.12.2014Radiat Oncol 2014; 9:270
Putora Paul Martin, Panje Cédric, Papachristofilou Alexandros, Pra Alan, Hundsberger Thomas, Plasswilm Ludwig
Reifung und Sterben
Renz M. Reifung und Sterben. punktum 2014; Dez 2014
01.12.2014Reifung und Sterben
01.12.2014punktum 2014; Dez 2014
Renz Monika
Chancen letzter Reifung
Renz M. Chancen letzter Reifung. Bioethica Forum 2014; 2014:142-143.
01.12.2014Chancen letzter Reifung
01.12.2014Bioethica Forum 2014; 2014:142-143
Renz Monika
Computer-Based Clinical Decision Support Systems and Patient-Reported Outcomes: A Systematic Review
Blum D, Raj S, Oberholzer R, Riphagen I, Strasser F, Kaasa S, EURO IMPACT, European Intersectorial Multidisciplinary Palliative Care Research Training. Computer-Based Clinical Decision Support Systems and Patient-Reported Outcomes: A Systematic Review. Patient 2014
29.11.2014Computer-Based Clinical Decision Support Systems and Patient-Reported Outcomes: A Systematic Review
29.11.2014Patient 2014
Blum David, Raj Sunil X, Oberholzer Rolf, Riphagen Ingrid I, Strasser Florian, Kaasa Stein, EURO IMPACT, European Intersectorial Multidisciplinary Palliative Care Research Training
[Nerve sonography of intraneural ganglia as cause painful peroneal palsies: a case series]
Schilg L, Hägele-Link S, Felbecker A, Gers B, Weber J, Tettenborn B, Hundsberger T. [Nerve sonography of intraneural ganglia as cause painful peroneal palsies: a case series]. Praxis (Bern 1994) 2014; 103:1433-8.
26.11.2014[Nerve sonography of intraneural ganglia as cause painful peroneal palsies: a case series]
26.11.2014Praxis (Bern 1994) 2014; 103:1433-8
Schilg Lenka, Hägele-Link Stefan, Felbecker Ansgar, Gers Bettina, Weber Johannes, Tettenborn Barbara, Hundsberger Thomas
Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline
Hundsberger T (2014). Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline.
20.11.2014Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical Decline
20.11.20147th European Symposium on Steps Forward in Pompe Disease
Hundsberger Thomas
Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis
Rocha P, Morgan C, Templeton A, Pond G, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat 2014; 37:772-6.
20.11.2014Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis
20.11.2014Oncol Res Treat 2014; 37:772-6
Rocha Pedro, Morgan Charity J, Templeton Arnoud, Pond Gregory R, Naik Gurudatta, Sonpavde Guru
External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation
Müller K, Zwiener I, Kortmann R, Paulsen F, Hundsberger T, Kramm C, Janssens G, Friedrich C, von Bueren A, Compter I, Henke G, Baumert B. External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation. Pract Radiat Oncol 2014; 5:e143-50.
18.11.2014External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation
18.11.2014Pract Radiat Oncol 2014; 5:e143-50
Müller Klaus, Zwiener Isabella, Kortmann Rolf-Dieter, Paulsen Frank, Hundsberger Thomas, Kramm Christof M, Janssens Geert, Friedrich Carsten, von Bueren André O, Compter Inge, Henke Guido, Baumert Brigitta G
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2014; 87:85-7.
18.11.2014Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
18.11.2014Lung Cancer 2014; 87:85-7
Schmid S, Siano Marco, Joerger M, Rodriguez Regulo, Müller J, Früh M
Management of von Hippel-Lindau Disease: An Interdisciplinary Review
Schmid S, Rothermundt C, Weber J, van Leyen K, Sulz M, Stöckli S, Krull I, Krek W, Kloos P, Heinimann K, Hader C, Greiner J, Engeler D, Brändle M, Binet F, Gillessen Sommer S, Hundsberger T. Management of von Hippel-Lindau Disease: An Interdisciplinary Review. Oncol Res Treat 2014; 37:761-771.
17.11.2014Management of von Hippel-Lindau Disease: An Interdisciplinary Review
17.11.2014Oncol Res Treat 2014; 37:761-771
Schmid Sabine, Rothermundt Christian, Weber Johannes, van Leyen Karin, Sulz Michael, Stöckli Sandro, Krull Ina, Krek Willy, Kloos Patrik, Heinimann Karl, Hader Claudia, Greiner Jeannette, Engeler Daniel, Brändle Michael, Binet Françoise-Isabelle, Gillessen Sommer Silke, Hundsberger Thomas
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Gnant M, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2014; 26:313-20.
17.11.2014Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
17.11.2014Ann Oncol 2014; 26:313-20
Gnant M, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer Michael, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Metabolism of the taxanes including nab-paclitaxel
Jörger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014:1-12.
14.11.2014Metabolism of the taxanes including nab-paclitaxel
14.11.2014Expert Opin Drug Metab Toxicol 2014:1-12
Jörger Markus